Cohort 3: hatg, csa (dose reduced), epag day 1 to month 6 (DrugBank: hATG)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
60 | Aplastic anemia | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01623167 (ClinicalTrials.gov) | July 2, 2012 | 14/6/2012 | Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia | Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia | Severe Aplastic Anemia | Drug: Cohort 1: hATG, CsA, EPAG Day 14 to Month 6;Drug: Cohort 2: hATG, CsA, EPAG Day 14 to Month 3;Drug: Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6;Drug: Extension Cohort | National Heart, Lung, and Blood Institute (NHLBI) | Novartis | Recruiting | 2 Years | 95 Years | All | 207 | Phase 1;Phase 2 | United States |